University of Melbourne
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Melbourne sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).
University of Melbourne: 3 sponsored US clinical trials, 1 recruiting.
University of Melbourne sponsors 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 2 completed. 1 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Staphylococcus Aureus Bacteremia, with 1 trials.
Upper-quartile sponsor footprint
University of Melbourne sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
3 total, page 1 of 1
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 4 | 1 |
Therapeutic Areas
Where University of Melbourne enrollment is open (later-stage tilt)
1 recruiting of 3 indexed (33% open); 2 completed (67%).
Phase mix: 1 late (III/IV) vs 0 early (I/II) (later-stage heavy).
Top condition: Staphylococcus Aureus Bacteremia (1 trial), 0 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Melbourne: open-pipeline peers nationwide
Peers matched on 3 registered trials and 33% open enrollment, not the therapeutic-area sidebar.
University of Melbourne sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 3 trials (± recruiting share)
- 10xBio · 3 trials · 0% recruiting
- 22nd Century Group · 3 trials · 0% recruiting
- AA Secord · 3 trials · 0% recruiting
- AAADRS Clinical Research Center · 3 trials · 0% recruiting
Sponsors near 33% open enrollment (± trial volume)
- Aadi Bioscience · 33% recruiting · 9 trials
- Aaron Cook · 33% recruiting · 3 trials
- Abivax S.A. · 33% recruiting · 6 trials
- Actuated Medical · 33% recruiting · 3 trials
Related
What to do with this University of Melbourne page
3 registered trials is a research-attention snapshot, not an endorsement of University of Melbourne or any single study.
- 1 of University of Melbourne's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Staphylococcus Aureus Bacteremia is the condition University of Melbourne studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Staphylococcus Aureus Bacteremia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Melbourne pipeline card: 3 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.